الفهرس 
Gastric CancerOnly 14 pages are availabe for public view
 |  | from | 135 |  |  |
| | | from | 135 | | |
Abstract
Summary
Gastric cancer is the 3rd cause of cancer related deaths and fifth most common
malignant tumor worldwide .It`s prevalence is increasing in conjunction with
H.Pylori infection , smoking , alcohol consumption , bad nutritional habits
(smoked food , food rich in salt and nitrites , processed meat), obesity , genetic
predisposition .
Although application of imaging and endoscopic examination play important role
in the diagnosis of gastric cancer, their use are complex and expensive for
screening . However , we targeted non invasive , cheap and useful biomarker in
clinical practice for gastric cancer screening .
Gastrin-releasing peptide (GRP) is a neuropeptide hormone that was originally
isolated from porcine gastric tissue. It is widely distributed throughout the
mammalian nervous system,as well as the gastrointestinal and pulmonary tracts.
Progastrin-releasing peptide is a precursor form and a more stable precursor of
GRP, which is a biologically active protein that stimulates tumor cell proliferation.
It appears that the growth-stimulating properties of progastrin releasing peptide
may be responsible for aggressive tumor behavior . Numerous studies have
demonstrated that progastrin releasing peptide as a biomarker of small cell lung
cancer , However, few studies have measured the levels of the same biomarker in
patients with gastric cancer .
The current study was conducted at Damietta cardiology and gastroenterology
center in association with Ain Shams University Hospitals aiming to elucidate the
diagnostic value of serum progastrin releasing peptide in patients with gastric
cancer. A total of 75 subjects were enrolled in the current study, and they were
divided into three equal groups; the first one included 25 healthy controls, the91
second one included 25 patients with benign gastric lesions, while the third one
included 25 patients with malignant gastric lesions.
Our study showed the following findings :
CEA had sensitivity and specifity of 64% and 60 % for differentiating
between benign and malignant group which means low diagnostic ability of
CEA in detecting gastric cancer .
Progastrin Releasing peptide (Pro GRP) had 96% sensitivity and 96%
specifity in differentiating between benign and malignant groups which
means higher diagnostic abilities of Pro GRP in cancer stomach